Publikationen in Zusammenarbeit mit Forschern von University of Texas MD Anderson Cancer Center (20)

2024

  1. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

    American Journal of Hematology, Vol. 99, Núm. 4, pp. 586-595

2022

  1. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)

    Nature Medicine

  2. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781

  3. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

    Nature Medicine, Vol. 28, Núm. 3, pp. 557-567

2021

  1. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

    Leukemia, Vol. 35, Núm. 12, pp. 3542-3550

  2. Preclinical development of a humanized chimeric antigen receptor against B-cell maturation antigen for multiple myeloma

    Haematologica, Vol. 106, Núm. 1, pp. 173-184

2019

  1. Clonal hematopoiesis of indeterminate potential–associated mutations and risk of comorbidities in patients with myelodysplastic syndrome

    Cancer, Vol. 125, Núm. 13, pp. 2233-2241

2018

  1. Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases

    Leukemia, Vol. 32, Núm. 11, pp. 2512-2518

  2. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms

    Oncotarget, Vol. 9, Núm. 11, pp. 9714-9727

  3. Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia

    Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73

  4. The oncogenic RNA-binding protein SRSF1 regulates LIG1 in non-small cell lung cancer

    Laboratory Investigation, Vol. 98, Núm. 12, pp. 1562-1574

2017

  1. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

    Leukemia, Vol. 31, Núm. 2, pp. 318-324

  2. BCL6 antagonizes NOTCH2 to maintain survival of human follicular lymphoma cells

    Cancer Discovery, Vol. 7, Núm. 5, pp. 506-521

  3. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

    The Lancet, Vol. 390, Núm. 10094, pp. 555-566

  4. Current management of patients with chronic myelomonocytic leukemia

    Current Opinion in Oncology, Vol. 29, Núm. 1, pp. 79-87

  5. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies

    Cancer, Vol. 123, Núm. 24, pp. 4851-4859

  6. Preclinical activity of FF-10501-01, a novel inosine-5′-monophosphate dehydrogenase inhibitor, in acute myeloid leukemia

    Leukemia Research, Vol. 59, pp. 85-92

2012

  1. Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung

    Journal of Clinical Oncology, Vol. 30, Núm. 10, pp. 1129-1136

2011

  1. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q

    Leukemia, Vol. 25, Núm. 1, pp. 110-120

2007

  1. Phase I and Pharmacokinetic Study of Gemcitabine Administered at Fixed-Dose Rate, Combined with Docetaxel/Melphalan/Carboplatin, with Autologous Hematopoietic Progenitor-Cell Support, in Patients with Advanced Refractory Tumors

    Biology of Blood and Marrow Transplantation, Vol. 13, Núm. 11, pp. 1324-1337